{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T17:31:54Z","timestamp":1786555914019,"version":"build-2736575974"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014717","name":"National Natural Science Foundation of China National Outstanding Youth Science Fund Project","doi-asserted-by":"publisher","award":["82400232"],"award-info":[{"award-number":["82400232"]}],"id":[{"id":"10.13039\/100014717","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.leukres.2026.108282","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T06:38:26Z","timestamp":1784097506000},"page":"108282","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Analysis of the efficacy and safety of the IVD\/EM maintenance regimen as post-remission treatment for adult patients with T-cell lymphoblastic lymphoma\/leukemia"],"prefix":"10.1016","volume":"168","author":[{"given":"Ziteng","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yige","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingzhi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2026.108282_bib1","first-page":"353","article-title":"of the diagnosis and treatment of adult T-cell lymphoblastic lymphoma in China (2023)","volume":"44","author":"The consensus","year":"2023","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"10.1016\/j.leukres.2026.108282_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11912-021-01168-x","article-title":"Lymphoblastic Lymphoma: a Concise Review","volume":"24","author":"Intermesoli","year":"2022","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.leukres.2026.108282_bib3","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2026.108282_bib4","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1182\/blood-2015-08-661702","article-title":"Early T-cell precursor acute lymphoblastic leukemia\/lymphoma (ETP-ALL\/LBL) in adolescents and adults: a high-risk subtype","volume":"127","author":"Jain","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2026.108282_bib5","doi-asserted-by":"crossref","first-page":"4379","DOI":"10.1182\/blood-2002-01-0110","article-title":"Outcome of adult patients with T-lymphoblastic lymphoma treated according to protocols for acute lymphoblastic leukemia","volume":"99","author":"Hoelzer","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2026.108282_bib6","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00428-022-03448-8","article-title":"International Consensus Classification of acute lymphoblastic leukemia\/lymphoma","volume":"482","author":"Duffield","year":"2023","journal-title":"Virchows Arch."},{"key":"10.1016\/j.leukres.2026.108282_bib7","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/sj.leu.2403682","article-title":"Allogeneic hematopoietic stem cell transplantation provides sustained long-term survival for patients with adult T-cell leukemia\/lymphoma","volume":"19","author":"Fukushima","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2026.108282_bib8","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.3109\/10428191003754616","article-title":"T-lymphoblastic leukemia\/lymphoma: a single center retrospective study of outcome","volume":"51","author":"Fortune","year":"2010","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.leukres.2026.108282_bib9","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1182\/blood-2002-05-1483","article-title":"A comparison of allogeneic and autologous bone marrow transplantation for lymphoblastic lymphoma","volume":"101","author":"Levine","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2026.108282_bib10","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2026.108282_bib11","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","article-title":"Using the Common Terminology Criteria for Adverse Events (CTCAE - Version 5.0) to Evaluate the Severity of Adverse Events of Anticancer Therapies","volume":"112","author":"Freites-Martinez","year":"2021","journal-title":"Actas Dermosifiliogr. (Engl. Ed. )"},{"key":"10.1016\/j.leukres.2026.108282_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217460","article-title":"Clinical features and prognostic nomogram for therapy-related acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation","volume":"612","author":"Li","year":"2025","journal-title":"Cancer Lett."},{"key":"10.1016\/j.leukres.2026.108282_bib13","article-title":"Treatment options for adult intermediate-risk AML patients in CR1: Allo-HSCT or chemotherapy?","volume":"4","author":"Wang","year":"2023","journal-title":"Innov. (Camb. )"},{"key":"10.1016\/j.leukres.2026.108282_bib14","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1097\/PPO.0b013e31826b1232","article-title":"Adult lymphoblastic lymphoma","volume":"18","author":"Portell","year":"2012","journal-title":"Cancer J."},{"key":"10.1016\/j.leukres.2026.108282_bib15","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-78334-x","article-title":"Indication and benefit of upfront hematopoietic stem cell transplantation for T-cell lymphoblastic lymphoma in the era of ALL-type induction therapies","volume":"10","author":"Morita-Fujita","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.leukres.2026.108282_bib16","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1023\/A:1008202808144","article-title":"Role of induction chemotherapy and bone marrow transplantation in adult lymphoblastic lymphoma: a report on 62 patients from a single center","volume":"9","author":"Bouabdallah","year":"1998","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.leukres.2026.108282_bib17","first-page":"767","article-title":"Role of allogenic bone marrow transplantation in adolescent or adult patients with acute lymphoblastic leukaemia or lymphoblastic lymphoma in first remission","volume":"14","author":"De Witte","year":"1994","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.leukres.2026.108282_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217664","article-title":"Allogeneic versus autologous hematopoietic stem cell transplantation for adult T-lymphoblastic lymphoma: A real-world multicenter analysis in China","volume":"621","author":"Wang","year":"2025","journal-title":"Cancer Lett."},{"key":"10.1016\/j.leukres.2026.108282_bib19","article-title":"Selection of hematopoietic stem cell transplantation for T-cell lymphoblastic lymphoma","volume":"13","author":"Li","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.leukres.2026.108282_bib20","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-72897-9","article-title":"TBI\/Cy followed by auto-HSCT is a good choice next to allo-HSCT for patients with T-LBL\/ALL","volume":"14","author":"Mao","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.leukres.2026.108282_bib21","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/S0140-6736(98)11135-2","article-title":"Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation","volume":"353","author":"Sykes","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.leukres.2026.108282_bib22","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1182\/blood-2003-12-4428","article-title":"Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma","volume":"104","author":"Thomas","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2026.108282_bib23","doi-asserted-by":"crossref","first-page":"577","DOI":"10.3109\/10428199609054867","article-title":"Adult lymphoblastic lymphoma: clinical features and prognostic factors in 53 patients","volume":"23","author":"Zinzani","year":"1996","journal-title":"Leuk. Lymphoma"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212626001268?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212626001268?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T16:37:09Z","timestamp":1786552629000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212626001268"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":23,"alternative-id":["S0145212626001268"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2026.108282","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Analysis of the efficacy and safety of the IVD\/EM maintenance regimen as post-remission treatment for adult patients with T-cell lymphoblastic lymphoma\/leukemia","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2026.108282","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108282"}}